<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368519">
  <stage>Registered</stage>
  <submitdate>11/05/2015</submitdate>
  <approvaldate>2/06/2015</approvaldate>
  <actrnumber>ACTRN12615000566538</actrnumber>
  <trial_identification>
    <studytitle>Studying the antidepressant effects of intravenous ketamine in patients with major depressive disorder</studytitle>
    <scientifictitle>Studying the antidepressant effects of intravenous ketamine in patients with major depressive disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous Ketamine 0.5mg/kg infusion once per week for 2 weeks</interventions>
    <comparator>Comparator group: Intravenous Scopolamine 4 mcg/kg infusion once per week for 2 weeks
Control group: Intravenous Saline (placebo) infusion once per week for 1 week</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in depression severity pre- and post-intervention using Montgomery-Asberg Depression Rating Scale</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impressions Scale</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quick Inventory of Depressive Symptamatology</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Psychiatric Rating Scale</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Young Mania Rating Scale</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Anxiety Rating Scale</outcome>
      <timepoint>Baseline, day 1 and day 3 after each infusion, and weekly up to 6 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional connectivity with magnetic resonance imaging</outcome>
      <timepoint>Baseline and post second infusion.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Major depressive episode according to DSM-IV-TR Disorders
- Montgomery-Asberg Depression Rating Scale score of at least 20
- On stable doses of oral antidepressant medication
- Ability to provide informed consent</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Any unstable medical condition or clinically relevant abnormality that is likely to compromise study conduct, evaluation or safety
- Schizophrenia and other psychotic disorders, bipolar disorder, obsessive-compulsive disorder, eating disorder, substance-related disorders
- Drug allergy to ketamine or scopolamine
- Use of adjunct medications for depression and TCAs
- Pregnant or breast-feeding women
- Inability to follow procedures in the study protocol for any reason</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>4/06/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>National University of Singapore</primarysponsorname>
    <primarysponsoraddress>National University of Singapore
1E Kent Ridge Road, NUHS Tower Block, Level 11, Singapore 119228 </primarysponsoraddress>
    <primarysponsorcountry>Singapore</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>National University of Singapore</fundingname>
      <fundingaddress>Clinician Scientist Unit (CSU), Yong Loo Lin School of Medicine, National University of Singapore
1E Kent Ridge Road, NUHS Tower Block, Level 11, Singapore 119228 </fundingaddress>
      <fundingcountry>Singapore</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>National University Hospital</sponsorname>
      <sponsoraddress>National University Hospital
1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228 </sponsoraddress>
      <sponsorcountry>Singapore</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomised controlled trial aims to study the add-on effects of intravenous ketamine to standard oral antidepressant treatment. We hypothesise that this combination may bring about more rapid antidepressant effects compared with oral antidepressant treatment alone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NHG Domain Specific Review Board</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/04/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Singapore</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Johnson Fam</name>
      <address>Department of Psychological Medicine, NUHS Tower Block Level 9, 1E Lower Kent Ridge Road, Singapore 119 228</address>
      <phone>+65 67795555 </phone>
      <fax />
      <email>pcmjf@nus.edu.sg</email>
      <country>Singapore</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Johnson Fam</name>
      <address>Department of Psychological Medicine, NUHS Tower Block Level 9, 1E Lower Kent Ridge Road, Singapore 119228</address>
      <phone>+65 67795555</phone>
      <fax />
      <email>pcmjf@nus.edu.sg</email>
      <country>Singapore</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Johnson Fam</name>
      <address>Department of Psychological Medicine, NUHS Tower Block Level 9, 1E Lower Kent Ridge Road, Singapore 119228</address>
      <phone>+65 67795555</phone>
      <fax />
      <email>pcmjf@nus.edu.sg</email>
      <country>Singapore</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>